Stock 002393 TIANJIN LISHENG PHARMACEUTICAL CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Tianjin Lisheng Pharmaceutical Co.,Ltd.

Equities

002393

CNE100000NJ9

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
24.93 CNY +0.69% Intraday chart for Tianjin Lisheng Pharmaceutical Co.,Ltd. -0.32% -4.48%
Apr. 24 Tianjin Lisheng Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Mar. 22 Tianjin Lisheng Pharmaceutical Co.,Ltd. Proposes Cash Dividend for the Year 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 3,928 4,986 3,720 3,943 3,917 4,810
Enterprise Value (EV) 1 2,461 3,321 2,178 2,326 1,969 2,623
P/E ratio 21.3 x 26.5 x 408 x 32.3 x 41.7 x 13.2 x
Yield 1.39% 1.1% 0.49% 1.39% 1.41% 2.3%
Capitalization / Revenue 2.61 x 3.09 x 3.26 x 3.61 x 3.42 x 4.17 x
EV / Revenue 1.64 x 2.06 x 1.91 x 2.13 x 1.72 x 2.27 x
EV / EBITDA 11.1 x 13.6 x 21.2 x 26.7 x 15.7 x 14.6 x
EV / FCF -1,387 x 21.9 x -17 x 273 x 6.52 x 118 x
FCF Yield -0.07% 4.56% -5.87% 0.37% 15.3% 0.85%
Price to Book 1.22 x 1.13 x 0.86 x 0.89 x 0.9 x 0.97 x
Nbr of stocks (in thousands) 182,455 182,455 182,455 182,455 183,993 184,277
Reference price 2 21.53 27.33 20.39 21.61 21.29 26.10
Announcement Date 3/24/19 4/22/20 3/23/21 3/24/22 3/23/23 3/21/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 1,504 1,615 1,141 1,092 1,147 1,153
EBITDA 1 222.1 244.3 103 87.19 125.5 179.4
EBIT 1 167.9 184.3 40.29 28.66 61.05 113.6
Operating Margin 11.17% 11.41% 3.53% 2.62% 5.32% 9.85%
Earnings before Tax (EBT) 1 214 216.8 30.93 137.1 118.4 420.2
Net income 1 185 188.1 8.615 122.1 93.61 361.8
Net margin 12.3% 11.65% 0.76% 11.18% 8.16% 31.38%
EPS 2 1.010 1.030 0.0500 0.6700 0.5100 1.970
Free Cash Flow 1 -1.775 151.4 -128 8.514 301.9 22.21
FCF margin -0.12% 9.37% -11.22% 0.78% 26.33% 1.93%
FCF Conversion (EBITDA) - 61.97% - 9.77% 240.58% 12.38%
FCF Conversion (Net income) - 80.46% - 6.97% 322.51% 6.14%
Dividend per Share 2 0.3000 0.3000 0.1000 0.3000 0.3000 0.6000
Announcement Date 3/24/19 4/22/20 3/23/21 3/24/22 3/23/23 3/21/24
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 1,467 1,665 1,542 1,617 1,949 2,187
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -1.78 151 -128 8.51 302 22.2
ROE (net income / shareholders' equity) 5.88% 4.93% 0.2% 2.8% 2.14% 7.82%
ROA (Net income/ Total Assets) 2.76% 2.51% 0.49% 0.35% 0.73% 1.28%
Assets 1 6,696 7,504 1,761 34,818 12,860 28,222
Book Value Per Share 2 17.60 24.20 23.60 24.20 23.60 26.90
Cash Flow per Share 2 8.480 9.270 8.560 9.050 9.750 10.90
Capex 1 104 90.5 101 88.2 40.9 61.7
Capex / Sales 6.95% 5.6% 8.82% 8.08% 3.57% 5.35%
Announcement Date 3/24/19 4/22/20 3/23/21 3/24/22 3/23/23 3/21/24
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Generic Pharmaceuticals

1st Jan change Capi.
TIANJIN LISHENG PHARMACEUTICAL CO.,LTD. Stock Tianjin Lisheng Pharmaceutical Co.,Ltd.
-4.48% 634M
SUN PHARMACEUTICAL INDUSTRIES LTD. Stock Sun Pharmaceutical Industries Ltd.
+19.62% 43.34B
OTSUKA HOLDINGS CO., LTD. Stock Otsuka Holdings Co., Ltd.
+20.44% 21.96B
SANDOZ GROUP AG Stock Sandoz Group AG
+10.86% 14.09B
CIPLA LIMITED Stock Cipla Limited
+13.07% 13.64B
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+37.46% 11.43B
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-8.59% 6.86B
THE MEDICINES COMPANY Stock The Medicines Company
-0.05% 6.79B
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 5.73B
ASPEN PHARMACARE HOLDINGS LIMITED Stock Aspen Pharmacare Holdings Limited
+8.46% 5.22B
Generic Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 002393 Stock
  4. Financials Tianjin Lisheng Pharmaceutical Co.,Ltd.